/ /

CLINICAL

Ubiquitous steroid use posing unwitting cause for glaucomaAll corticosteroids matter when it comes to the risk of an intraocular pressure (IOP) response, and that is an important point for ophthalmologists to remember because opportunities for corticosteroid exposure are growing.
Lifestyle modifications may help control glaucoma progressionYvonne Ou, MD, gives patients advice about physical activity, body positions to avoid, leafy green vegetables, caffeine, and blood pressure treatment–as suggestions to help patients control their glaucoma progression.
Home-monitoring devices offer better insight to figure out IOPL. Jay Katz, MD. outlined the benefits of home IOP monitoring. These devices will offer a wealth of information that should lead to increased understanding of glaucoma and better patient care.
End-stage glaucoma requires outside-of-the-box managementAlthough the aim of glaucoma management is to maintain visual function, the role of the ophthalmologist does not end once a patient has lost useful vision. Robert L. Stamper, MD, discussed care for patients with end-stage glaucoma.
Evolution in glaucoma surgery mounting with MIGS proceduresAn expanding armamentarium of minimally invasive and micro-invasive glaucoma surgery procedures is transforming glaucoma management.
Welcome to the 2017 Glaucoma 360Adrienne Graves, PhD, and Andrew Iwach, MD, welcome attendees to Glaucoma 360 with their focus set on next year's conference, February 9, 2018 in San Francisco.
What you missed at Glaucoma 360 this year
What you missed at Glaucoma 360 this yearSee the highlights and program overview from the Glaucoma Research Foundation's 2017 Glaucoma 360!
Teleglaucoma redefining role in future of blindness prevention'Teleglaucoma’ is feasible and can play a major role in blindness prevention. Telemedicine and teleglaucoma are going to be an important part of how physicians take care of patients in the United States and worldwide.
OCT imaging yields better visualizationFuture increases in imaging speed will improve performance and functionality for OCT and OCT angiography (OCTA), said James Fujimoto, PhD.
Glaucoma, dry eye drugs center of pharmaceutical opportunitiesThe pharma drought is coming to a close. After decades of same-old medications for glaucoma and ocular surface disease, a series of new agents with new mechanisms of action (MOA) are moving toward marketing approval.